Menu

Blog

Archive for the ‘biotech/medical’ category: Page 1062

Jan 7, 2022

Rockefeller saliva test for COVID-19 outperforms commercial swab tests

Posted by in categories: biotech/medical, surveillance

In the early days of the pandemic, with commercial COVID tests in short supply, Rockefeller’s Robert B. Darnell developed an in-house assay to identify positive cases within the Rockefeller community. It turned out to be easier and safer to administer than the tests available at the time, and it has been used tens of thousands of times over the past nine months to identify and isolate infected individuals working on the university’s campus.

Now, a new study in PLoS confirms that Darnell’s test performs as well, if not better, than FDA-authorized nasal and oral swab tests. In a direct head-to-head comparison of 162 individuals who received both Rockefeller’s “DRUL” saliva test and a conventional swab test, DRUL caught all of the cases that the swabs identified as positive—plus four positive cases that the swabs missed entirely.

“This research confirms that the test we developed is sensitive and safe,” says Darnell, the Robert and Harriet Heilbrunn professor and head of the Laboratory of Molecular Neuro-Oncology. “It is inexpensive, has provided excellent surveillance within the Rockefeller community, and has the potential to improve safety in communities as the pandemic drags on.”

Jan 6, 2022

Pig brain cells may have cured a sea lion’s epilepsy—are humans next?

Posted by in categories: biotech/medical, neuroscience

The transplant in an animal named Cronutt points toward a new strategy to treat the disease. But many questions remain.

Jan 6, 2022

Pfizer and BioNTech Team Up to Develop the First mRNA-Based Shingles Vaccine

Posted by in category: biotech/medical

It affects one in three people in the U.S.

After co-developing the world’s first mRNA vaccine to combat COVID-19 and providing humanity with a game-changing tool to help address the most devastating pandemic in a century, Pfizer Inc. and BioNTech SE are teaming up once more to create a vaccine using the same technology for shingles, also known as herpes zoster, which is a debilitating and painful disease that affects about one in every three people in the United States.

An … See more.

Jan 6, 2022

Razer Just Unveiled Its New Mask. With a Microphone and Speakers?

Posted by in categories: biotech/medical, wearables

Switch your disposable masks with Zephyr.

If you think your voice has been dulled by wearing masks in this pandemic, then electronics company Razer has the product for you. Zephyr Pro is a wearable mask that has a voice amplification feature in addition to built-in speakers.

In January last year, Razer had unveiled the initial concept and called it Hazel. A year later, it is now Zephyr and Razer already has a Pro version of the product. At first glance, the Zephyr Pro does… See more.

Jan 6, 2022

The Moral Questions of Artificial Immortality (Artificial Biological Negligible Senescence)

Posted by in categories: biotech/medical, ethics, food, life extension

They say ‘I believe in nature. Nature is harmonious’. Every big fish is eating every smaller fish. Every organ is fighting constantly invading bacteria. Is that what you mean by harmony? There are planets that are exploding out there. Meteorites that hit another and blow up. What’s the purpose of that? What’s the purpose of floods? To drown people? In other words, if you start looking for purpose, you gotta look all over, take in the whole picture. So, man projects his own values into nature. — Jacque Fresco (March 13, 1916 — May 18, 2017)

When most of us use the word ‘nature‘, we really don’t know much about it in reality. — Ursa.

Jan 6, 2022

Second-generation AI-powered digital pills are changing the future of healthcare

Posted by in categories: biotech/medical, information science, robotics/AI

The first-generation AI systems did not address these needs, which led to a low adoption rate. But the second-generation AI systems are focused on a single subject – improving patients’ clinical outcomes. The digital pills combine a personalised second-generation AI system along with the branded or generic drug and improve the patient response as it increases adherence and overcomes the loss of response to chronic medications. It works on improving the effectiveness of drugs and therefore reducing healthcare costs and increasing end-user adoption.

There are many examples to prove that there is a partial or complete loss of response to chronic medications. Cancer drug resistance is a major obstacle for the treatment of multiple malignancies, one-third of epileptics develop resistance to anti-epileptic drugs; also, a similar percentage of patients with depression develop resistance to anti-depressants. Other than the loss of response to chronic medications, low adherence is also a common problem for many NCDs. A little less than 50% of severely asthmatic patients adhere to inhaled treatments, while 40% of hypertensive patients show non-adherence.

The second-generation systems are aimed at improving outcomes and reducing side effects. To overcome the hurdle of biases induced by big data, these systems implement an n = 1 concept in a personalised therapeutic regimen. This focus of the algorithm improves the clinically meaningful outcome for an individual subject. The personalised closed-loop system used by the second-generation system is designed to improve the end-organ function and overcome tolerance and loss of effectiveness.

Jan 6, 2022

Omicron might have come from a mouse, but what kind of mouse?

Posted by in categories: biotech/medical, genetics

Researchers from the Chinese Academy of Sciences in Beijing recently reported intriguing new evidence for a possible mouse origin of the Omicron variant. Their paper, posted on the BioRxiv preprint server, was quickly picked up and published a few days later by the Journal of Genetics and Genomics, and defies the prevailing theory which claims that the polymutant spike sequence of Omicron must have evolved under protracted infection in a severely immunocompromised patient.

Their main idea is that a mouse could have somehow been infected with the human virus by “reverse zoonotic transfer,” whereupon the virus evolved all or many of its 45 novel mutations, and then subsequently was transferred back to humans. While this theory might explain why Omicron appears so anomalous when plotted on a phylogenetic tree against the usual suspects, there is one major problem: The mouse homolog of the human ACE2 receptor (hACE2), which the virus typically uses to gain entry into , has little affinity for the standard issue SARS-CoV-2 spike protein.

So little in fact, that in order to study the virus in this preferred research animal, scientists must artificially introduce hACE2 in order to create mice that show any significant respiratory distress upon infection. These are made in several ways, each showing unique tissue tropisms, penetrance and correspondingly different effects. Researchers have conducted knock-in experiments in which the human hACE2 sequence is integrated into the and induced under the control of a number of different promoters. Adenoviruses can also be used to infect cells and create replicating plasmids that propagate the hACE2 code.

Jan 6, 2022

What to Know

Posted by in category: biotech/medical

A COVID testing site says it has detected what is believed to be the first ‘flurona’ co-infection, a combination of influenza and coronavirus, in Los Angeles County.

Jan 6, 2022

A Texas team comes up with a COVID vaccine that could be a global game changer

Posted by in category: biotech/medical

Peter Hotez and Maria Elena Bottazzi used an oldie-but-goodie technology to devise a vaccine that’s easy to make — and relatively cheap. India has already ordered 300 million doses.

Jan 6, 2022

Parkinson’s Drug Discovery Collaboration Between Astrogen, Iktos to Leverage AI Platform

Posted by in categories: biotech/medical, chemistry, information science, robotics/AI

Artificial intelligence drug design company Iktos, and South Korean clinical research biotech Astrogen announced today a collaboration with the goal of discovering small-molecule pre-clinical drug candidates for a specific, undisclosed, marker of Parkinson’s disease (PD).

Under the terms of the agreement, whose value was not disclosed, Iktos will apply its generative learning algorithms which seek to identify new molecular structures with the potential address the target in PD. Astrogen, which has a focus of the development of therapeutics for “intractable neurological diseases,” will provide in-vitro and in-vivo screening of lead compounds and pre-clinical compounds. While both companies will contribute to the identification of new small-molecule candidates, Astrgoen will lead the drug development process from the pre-clinical stages.

“Our objective is to expedite drug discovery and achieve time and cost efficiencies for our global collaborators by using Iktos’s proprietary AI platform and know-how,” noted Yann Gaston-Mathé, president and CEO of Paris-based Iktos in a press release. “We are confident that together we will be able to identify promising novel chemical matter for the treatment of intractable neurological diseases. Our strategy has always been to tackle challenging problems alongside our collaborators where we can demonstrate value generation for new and on-going drug discovery projects.”